IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP) Files An 8-K Financial Statements and ExhibitsItem 9.01.Financial Statements and Exhibits
d)Exhibits.
The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.
| Exhibit No. | Description |
| 99.1 | Press Release, dated December 6, 2018 |
IMMUNE PHARMACEUTICALS INC ExhibitEX-99.1 2 tv508593_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders Meeting adjourned in order to gather additional votes Fort Lee,…To view the full exhibit click here
About IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP)
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
